Loading
Alzheimer's Disease Research and Treatments / Cholinesterase and Neurodegenerative Diseases · Journal article
Russian Journal of Bioorganic Chemistry · July 28, 2026
Raises a question worth testing. It does not answer one.
This is an early-stage lead identification study describing the synthesis of seven novel Schiff base derivatives and their in vitro inhibition of cholinesterases and bacterial growth. PSD2 showed superior AChE inhibition (IC50 = 2.71 µM) compared to galantamine (IC50 = 20.3 µM) and PSD2 and PSD4 showed low MIC values (0.8–2.0 µmol/mL) against bacterial strains. No animal efficacy, toxicity, pharmacokinetics, or clinical data are provided, so these compounds remain preclinical leads without evidence of safety or in vivo activity.
In vitro chemical synthesis and screening with molecular docking. Purified recombinant or natural AChE and BuChE enzymes; unspecified Gram-positive and Gram-negative bacterial strains; no human or animal subjects. Intervention: Seven novel 4-aminoantipyrine-derived Schiff base compounds (PSD1–PSD7), with PSD2 identified as the lead candidate. Compared with: Galantamine (cholinesterase reference) and gentamicin (antibacterial reference).
PSD2 demonstrated AChE inhibition with IC50 = 2.71 µM and selectivity ratio = 10.62, outperforming galantamine (IC50 = 20.3 µM, selectivity ratio = 4.24) PSD2 and PSD4 showed broad-spectrum antimicrobial activity with MIC values of 0.8–2.0 µmol/mL, comparable to gentamicin Molecular docking predicted PSD2 binding scores of –10.7 kcal/mol for AChE and –10.1 kcal/mol for BuChE relative to galantamine
No toxicity, solubility, stability, or off-target activity data reported
These results identify promising chemical scaffolds for further development but provide no evidence of safety, tolerability, pharmacokinetics, or efficacy in animals or humans. Considerable preclinical work including toxicity assessment, absorption/distribution/metabolism/excretion characterization, and animal disease models would be required before clinical consideration.
This is an early-stage chemical synthesis and in vitro screening study with no animal or clinical data; it raises the question whether these compounds merit further development but does not yet answer whether they are safe or effective in disease.
As stated by the source record.
Quoted from the source exactly as published.
These results identify promising chemical scaffolds for further development but provide no evidence of safety, tolerability, pharmacokinetics, or efficacy in animals or humans. Considerable preclinical work including toxicity assessment, absorption/distribution/metabolism/excretion characterization, and animal disease models would be required before clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Objective: Alzheimer’s disease (AD) and microbial infections represent critical global health challenges, particularly within aging populations. Owing to their structural versatility and multi-target pharmacophores, Schiff bases serve as privileged scaffolds for the design of dual-acting therapeutic agents targeting both AD progression and infectious pathogens. Methods: In this study, a novel series of seven Schiff base derivatives (PSD1–PSD7) was synthesized and evaluated for their cholinesterase inhibitory potency and antibacterial efficacy. Antibacterial activity against Gram-positive and Gram-negative strains was quantified via zone of inhibition and minimum inhibitory concentration (MIC) assays. Inhibitory profiles against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) were systematically determined. Furthermore, molecular docking and binding pocket analyses were performed on AChE (PDB ID: 1EVE), BuChE (PDB ID: 7AWH), and peptide deformylase (PDB ID: 1G2A) to elucidate the structural basis of enzyme inhibition and microbial survival disruption. Results and Discussion: Among the synthesized library, derivative PSD2 emerged as the most potent candidate, displaying remarkable AChE inhibition (IC50 = 2.71 µM, selectivity ratio = 10.62) that significantly outperformed the reference drug galantamine (IC50 = 20.3 µM, selectivity ratio = 4.24). In antimicrobial assays, compounds PSD2 and PSD4 exhibited broad-spectrum efficacy with low MIC values (0.8–2.0 µmol/mL), comparable to the standard antibiotic gentamicin. Computational molecular docking corroborated these experimental findings; PSD2 exhibited superior binding affinities within the catalytic gorges of both cholinesterases relative to galantamine, yielding docking scores of –10.7 kcal/mol for AChE and –10.1 kcal/mol for BuChE. Conclusions: A new series of functionally diverse Schiff base derivatives was designed, synthesized, and biologically validated. The exceptional dual cholinesterase inhibition and broad-spectrum antimicrobial profiles demonstrated by PSD2 and PSD4 underscore their potential as multifunctional lead architectures for disease-modifying therapeutic development.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.